-
NORDIMET (methotrexate) Self-Injection Pen now available for Treatment of Rheumatoid Arthritis and Psoriasis/Psoriatic Arthritis in Canada
-Press Release Toronto, August 5, 2024 – Linepharma International Inc., a subsidiary of Nordic Group B.V. (NORDIC PHARMA), is pleased…
0 -
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES THE LAUNCH OF LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE.
-Nordic Pharma attending Kiawah Eye to share this innovation with ophthalmology leaders. BERWYN, PA – Nordic Pharma, Inc., a subsidiary…
-
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
-Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in…
-
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., ANNOUNCES JAI G. PAREKH, MD, MBA AS CHIEF COMMERCIAL OFFICER, EYE CARE U.S.
-BERWYN, PA — Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD,…
-
NORDIC PHARMA GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., COMPLETES ACQUISITION OF VISANT MEDICAL TO LAUNCH NOVEL THERAPY FOR DRY EYE DISEASE IN THE UNITED STATES
-BERWYN, PA — Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of…
-
Nordic Pharma joins the Pharmaceutical Supply Chain Initiative
-We are pleased to announce that Nordic Pharma has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member…
-
Draupnir Holdings Ltd have officially merged with Nordic Group B.V
-We are pleased to announce that as of January 2023, Draupnir Holdings Ltd which incorporates Altacor, ParaPharm Development & Transdermal…
-
Nordic Pharma files submission to health Canada for the marketing authorization of methotrexate autoinjector for treating rheumatoid arthritis in Canada
-Canada, March 29, 2022 – NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug…
-
European Commission approves Teysuno in metastatic colorectal cancer
-Nordic Pharma announces that on the 24th of January, the European Commission (EC) approved the new indication for Teysuno® (tegafur/gimeracil/oteracil)…
-
Positive EMA opinion for the use of Teysuno in metastatic colorectal cancer
-Nordic Pharma has announced that on 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a…
